Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

NCT06800768 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06800768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06800768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Recruiting
Start date
February 1, 2025
Completion date
January 31, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer